Opus Genetics (IRD) Net Margin (2010 - 2026)

Opus Genetics (IRD) has 8 years of Net Margin data on file, last reported at 3038.25% in Q1 2026.

• On a quarterly basis, Net Margin fell 285074.0% year-over-year to 3038.25% in Q1 2026; TTM through Mar 2026 was 805.46%, a 37604.0% decrease from a year earlier, with the FY2025 full-year figure at 275.97%, up 24743.0% from the prior year.
• Net Margin for Q1 2026 stood at 3038.25%, down from 158.06% in the prior quarter.
• Over the last five years, Net Margin for IRD reached as high as 85.17% in Q4 2022 and fell as low as 3038.25% in Q1 2026.
• Historically, Net Margin has averaged 496.5% across 5 years, with a median of 270.51% in 2025.
• Across the five-year window, Net Margin surged 65865 bps in 2025 and sank 285074 bps in 2026, its largest moves.
• Year by year, Net Margin stood at 85.17% in 2022, then sank by 433 bps to 283.56% in 2023, then sank by 188 bps to 816.71% in 2024, then jumped by 81 bps to 158.06% in 2025, then tumbled by 1822 bps to 3038.25% in 2026.
• Per Business Quant data, the three most recent Net Margin figures were 3038.25% in Q1 2026, 158.06% in Q4 2025, and 566.87% in Q3 2025.